PLRX (STOCKS)
Pliant Therapeutics, Inc. Common Stock
$1.080000
+0.010000 (+0.93%)
Prev close: $1.070000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Bernard Coulie
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $68.49M
- Employees
- 171
- P/E (TTM)
- -0.72
- P/B (TTM)
- 0.45
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $97.48M |
| Research and Development | $63.83M |
| Other Operating Expenses | $33.65M |
| Operating Income/Loss | -$97.48M |
| Income/Loss From Continuing Operations After Tax | -$92.29M |
| Income/Loss From Continuing Operations Before Tax | -$92.29M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$92.29M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$92.29M |
| Net Income/Loss Available To Common Stockholders, Basic | -$92.29M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.50 |
| Diluted Earnings Per Share | -$1.50 |
| Basic Average Shares | 123,295,914 |
| Diluted Average Shares | 123,295,914 |
| Common Stock Dividends | $0.00 |
| Assets | $189.88M |
| Current Assets | $163.14M |
| Noncurrent Assets | $26.74M |
| Fixed Assets | $2.41M |
| Other Non-current Assets | $24.33M |
| Liabilities | $42.96M |
| Current Liabilities | $16.48M |
| Accounts Payable | $1.53M |
| Wages | $3.18M |
| Other Current Liabilities | $11.78M |
| Noncurrent Liabilities | $26.47M |
| Long-term Debt | $0.00 |
| Equity | $146.93M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $146.93M |
| Liabilities And Equity | $189.88M |
| Net Cash Flow From Operating Activities | -$70.90M |
| Net Cash Flow From Operating Activities, Continuing | -$70.90M |
| Net Cash Flow From Investing Activities | $41.08M |
| Net Cash Flow From Investing Activities, Continuing | $41.08M |
| Net Cash Flow From Financing Activities | -$32.12M |
| Net Cash Flow From Financing Activities, Continuing | -$32.12M |
| Net Cash Flow | -$61.94M |
| Net Cash Flow, Continuing | -$61.94M |
| Comprehensive Income/Loss | -$92.36M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$92.69M |
| Other Comprehensive Income/Loss | -$72.32M |
| Other Comprehensive Income/Loss Attributable To Parent | -$396.00K |